Shoshana Levy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shoshana Levy has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
Achim Möller
158 shared publicationsAmy E. Saunders
158 shared publicationsAna Paula Trombone
158 shared publicationsAndreia Vieira
158 shared publications- Angharad E. Fenton-May
Henry Wellcome Building for Molecular Physiology, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, U.K.
158 shared publications - Anita R. Mistry158 shared publications
Latest Publications
- Open Access
- 20 June 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (26)
The molecular mechanism of CD81 antibody inhibition of metastasis
Metastases are reduced in CD81KO mice. In addition, a unique anti-CD81 antibody, 5A6, inhibits metastasis in vivo and invasion and migration in vitro. Here, we probed the structural components of CD81 required for the antimetastatic activity induced by 5A6. We found that the removal of either cholesterol or the intracellular domains of CD81 did not affect inhibition by the antibody. We show that the uniqueness of 5A6 is due not to increased affinity but rather to its recognition of a specific epitope on the large extracellular loop of CD81. Finally, we present a number of CD81 membrane-associated partners that may play a role in mediating the 5A6 antimetastatic attributes, including integrins and transferrin receptors.
- 20 June 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (26)
Open AccessThe molecular mechanism of CD81 antibody inhibition of metastasis
Metastases are reduced in CD81KO mice. In addition, a unique anti-CD81 antibody, 5A6, inhibits metastasis in vivo and invasion and migration in vitro. Here, we probed the structural components of CD81 required for the antimetastatic activity induced by 5A6. We found that the removal of either cholesterol or the intracellular domains of CD81 did not affect inhibition by the antibody. We show that the uniqueness of 5A6 is due not to increased affinity but rather to its recognition of a specific epitope on the large extracellular loop of CD81. Finally, we present a number of CD81 membrane-associated partners that may play a role in mediating the 5A6 antimetastatic attributes, including integrins and transferrin receptors.
- 1 May 2022
- Published by Elsevier in Trends in Cell Biology
- Vol. 32 (5) , 377-379
Tetraspanins in cell stemness and cancer initiation: markers or active players?
- 1 May 2022
- Published by Elsevier in Trends in Cell Biology
- Vol. 32 (5) , 377-379
Tetraspanins in cell stemness and cancer initiation: markers or active players?
- Open Access
- 28 January 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (5)
CD81 costimulation skews CAR transduction toward naive T cells
Significance: Chimeric antigen receptors (CARs) are engineered, artificial T cell receptors that can redirect cytotoxic immune T cells to eliminate cancer. Previous reports describe the benefit of less differentiated naive T cell subtypes for the purpose of CAR therapy. Here we test CD81, a T cell costimulator that preferentially activates naive T cells, for CAR engineering. We show that CD81 costimulation of naive T cells prior to CAR transduction can lead to enhanced CAR expression in this T cell subset.
- 28 January 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (5)
Open AccessCD81 costimulation skews CAR transduction toward naive T cells
Significance: Chimeric antigen receptors (CARs) are engineered, artificial T cell receptors that can redirect cytotoxic immune T cells to eliminate cancer. Previous reports describe the benefit of less differentiated naive T cell subtypes for the purpose of CAR therapy. Here we test CD81, a T cell costimulator that preferentially activates naive T cells, for CAR engineering. We show that CD81 costimulation of naive T cells prior to CAR transduction can lead to enhanced CAR expression in this T cell subset.
- 7 June 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (24)
Targeting the tetraspanin CD81 reduces cancer invasion and metastasis
Significance: CD81 belongs to the evolutionary conserved tetraspanin family of proteins that form specialized membranal platforms that facilitate a vast array of cellular processes. However, little is known about the consequences of these molecular interactions under normal or pathological conditions. Tetraspanins have no known natural ligands, but ligation by some antibodies induces functional consequences. Here we show that engagement of CD81 with 5A6 halts tumor invasion in vitro and reduces breast cancer metastasis in vivo. Altogether, these finding highlight the role of CD81 in cancer progression.
- 7 June 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (24)
Targeting the tetraspanin CD81 reduces cancer invasion and metastasis
Significance: CD81 belongs to the evolutionary conserved tetraspanin family of proteins that form specialized membranal platforms that facilitate a vast array of cellular processes. However, little is known about the consequences of these molecular interactions under normal or pathological conditions. Tetraspanins have no known natural ligands, but ligation by some antibodies induces functional consequences. Here we show that engagement of CD81 with 5A6 halts tumor invasion in vitro and reduces breast cancer metastasis in vivo. Altogether, these finding highlight the role of CD81 in cancer progression.
- Open Access
- 23 May 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 216 (7) , 1497-1508
CD81 is a novel immunotherapeutic target for B cell lymphoma
The tetraspanin CD81 was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target CD81, has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.
- 23 May 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 216 (7) , 1497-1508
Open AccessCD81 is a novel immunotherapeutic target for B cell lymphoma
The tetraspanin CD81 was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target CD81, has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.
- Open Access
- 12 June 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 1277
Immune Targeting of Tetraspanins Involved in Cell Invasion and Metastasis
Metastasis is the ultimate consequence of cancer progression and the cause of patients’ death across different cancer types. Patients with initial diagnosis of distant disease have a worst 5-year survival compared to patients with localized disease. Therapies that target primary tumors fail to eradicate distant dissemination of cancer. Recently, immunotherapies have improved the survival of patients with metastatic disease, such as melanoma and lung cancer. However, only a fraction of patients responds to immunotherapy modalities that target the host immune system. The need to identify new druggable targets that inhibit or prevent metastasis is, therefore, much needed. Tetraspanins have emerged as key players in regulating cell migration, invasion, and metastasis. By serving as molecular adaptors that cluster adhesion receptors, signaling molecules, and cell surface receptors; tetraspanins are involved in all steps of the metastatic cascade. They regulate cell proliferation, participate in EMT transition, modulate integrin-mediated cell adhesion, and participate in angiogenesis and invasion processes. Tetraspanins have also been shown to modulate metastasis indirectly through exosomes and by regulating cellular interactions in the immune system. Importantly, targeting individual tetraspanin with antibodies has impacted tumor progression. This review will focus on the contribution of tetraspanins to the metastatic process and their potential as therapeutic tumor targets.
- 12 June 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 1277
Open AccessImmune Targeting of Tetraspanins Involved in Cell Invasion and Metastasis
Metastasis is the ultimate consequence of cancer progression and the cause of patients’ death across different cancer types. Patients with initial diagnosis of distant disease have a worst 5-year survival compared to patients with localized disease. Therapies that target primary tumors fail to eradicate distant dissemination of cancer. Recently, immunotherapies have improved the survival of patients with metastatic disease, such as melanoma and lung cancer. However, only a fraction of patients responds to immunotherapy modalities that target the host immune system. The need to identify new druggable targets that inhibit or prevent metastasis is, therefore, much needed. Tetraspanins have emerged as key players in regulating cell migration, invasion, and metastasis. By serving as molecular adaptors that cluster adhesion receptors, signaling molecules, and cell surface receptors; tetraspanins are involved in all steps of the metastatic cascade. They regulate cell proliferation, participate in EMT transition, modulate integrin-mediated cell adhesion, and participate in angiogenesis and invasion processes. Tetraspanins have also been shown to modulate metastasis indirectly through exosomes and by regulating cellular interactions in the immune system. Importantly, targeting individual tetraspanin with antibodies has impacted tumor progression. This review will focus on the contribution of tetraspanins to the metastatic process and their potential as therapeutic tumor targets.
- 1 June 2018
- Published by Springer Nature
- p. 962-967
CD81
- 13 April 2017
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 45 (2) , 531-535
CD81 as a tumor target
CD81 participates in a variety of important cellular processes such as membrane organization, protein trafficking, cellular fusion and cell–cell interactions. In the immune system, CD81 regulates immune synapse, receptor clustering and signaling; it also mediates adaptive and innate immune suppression. CD81 is a gateway in hepatocytes for pathogens such as hepatitis C virus and Plasmodium; it also confers susceptibility to Listeria infection. These diverse biological roles are due to the tendency of CD81 to associate with other tetraspanins and with cell-specific partner proteins, which provide the cells with a signaling platform. CD81 has also been shown to regulate cell migration and invasion, and has therefore been implicated in cancer progression. Indeed, we have recently shown that CD81 contributes to tumor growth and metastasis. CD81 is expressed in most types of cancer, including breast, lung, prostate, melanoma, brain cancer and lymphoma, and the overexpression or down-regulation of this molecule has been correlated with either good or bad prognosis. Here, we discuss the role of CD81 in cancer and its potential therapeutic use as a tumor target.
- 13 April 2017
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 45 (2) , 531-535
CD81 as a tumor target
CD81 participates in a variety of important cellular processes such as membrane organization, protein trafficking, cellular fusion and cell–cell interactions. In the immune system, CD81 regulates immune synapse, receptor clustering and signaling; it also mediates adaptive and innate immune suppression. CD81 is a gateway in hepatocytes for pathogens such as hepatitis C virus and Plasmodium; it also confers susceptibility to Listeria infection. These diverse biological roles are due to the tendency of CD81 to associate with other tetraspanins and with cell-specific partner proteins, which provide the cells with a signaling platform. CD81 has also been shown to regulate cell migration and invasion, and has therefore been implicated in cancer progression. Indeed, we have recently shown that CD81 contributes to tumor growth and metastasis. CD81 is expressed in most types of cancer, including breast, lung, prostate, melanoma, brain cancer and lymphoma, and the overexpression or down-regulation of this molecule has been correlated with either good or bad prognosis. Here, we discuss the role of CD81 in cancer and its potential therapeutic use as a tumor target.
- 1 January 2016
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 6 (16)
Adoptive Transfer of Tumor Expanded Regulatory T Cells (Tregs)
Regulatory T cells (Tregs), a subset of CD4+CD25+ T cells, infiltrate tumors and suppress antitumor activity of effector T and NK cells. Depletion of Tregs by anti CD25+ antibodies has been shown to reduce tumor growth and metastasis (Olkhanud et al., 2009). Conversely, adoptive transfer of Tregs induced immune suppression and promoted tumor growth (Smyth et al., 2006; Janakiram et al., 2015). We have adoptively transferred Tregs to evaluate their immunosuppressive function in vivo. Our study (Vences-Catalan et al., 2015) compared the immunosuppressive efficacy of Tregs derived from tumor-bearing wild type to those of CD81KO mice. The following protocol could be adapted to any other source of Tregs.Lymph node or splenic tumor-induced Tregs are isolated and purified by a two-step procedure using CD4+CD25+ regulatory T cell isolation kit from MACS Miltenyi Biotec. First, CD4+ T cells are enriched by negative selection, followed by positive selection of CD25+ T cells. Tumor-induced purified Tregs (CD3+CD4+CD25+FoxP3+) are then co-injected subcutaneously together with tumor cells into naïve mice (Winn assay) (Winn, 1960). Tregs could also be injected intravenously once or several times, according to the research needs. The effect of the adoptively transferred Tregs on tumor growth is then measured by caliper or by in vivo imaging techniques. Bio-protocol is an online peer-reviewed protocol journal. Its mission is to make life science research more efficient and reproducible by curating and hosting high quality, free access protocols.
- 1 January 2016
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 6 (16)
Adoptive Transfer of Tumor Expanded Regulatory T Cells (Tregs)
Regulatory T cells (Tregs), a subset of CD4+CD25+ T cells, infiltrate tumors and suppress antitumor activity of effector T and NK cells. Depletion of Tregs by anti CD25+ antibodies has been shown to reduce tumor growth and metastasis (Olkhanud et al., 2009). Conversely, adoptive transfer of Tregs induced immune suppression and promoted tumor growth (Smyth et al., 2006; Janakiram et al., 2015). We have adoptively transferred Tregs to evaluate their immunosuppressive function in vivo. Our study (Vences-Catalan et al., 2015) compared the immunosuppressive efficacy of Tregs derived from tumor-bearing wild type to those of CD81KO mice. The following protocol could be adapted to any other source of Tregs.Lymph node or splenic tumor-induced Tregs are isolated and purified by a two-step procedure using CD4+CD25+ regulatory T cell isolation kit from MACS Miltenyi Biotec. First, CD4+ T cells are enriched by negative selection, followed by positive selection of CD25+ T cells. Tumor-induced purified Tregs (CD3+CD4+CD25+FoxP3+) are then co-injected subcutaneously together with tumor cells into naïve mice (Winn assay) (Winn, 1960). Tregs could also be injected intravenously once or several times, according to the research needs. The effect of the adoptively transferred Tregs on tumor growth is then measured by caliper or by in vivo imaging techniques. Bio-protocol is an online peer-reviewed protocol journal. Its mission is to make life science research more efficient and reproducible by curating and hosting high quality, free access protocols.
- 1 January 2016
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 6 (16)
Macrophage Polarization by Tumor-induced MDSCs Assay
- 1 January 2016
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 6 (16)
Macrophage Polarization by Tumor-induced MDSCs Assay